Indicators in the Sexual and reproductive health profiles have been updated with the latest data. The annual update to reproductive health indicators gives national and local data to inform planning for sexual health and contraceptive services for local populations. This includes information about inequalities such as deprivation, age and sex where this is available. These data are intended for use by local government and health service professionals. 

This release updates indicators relating to: 

• contraceptive prescribing for 2023
• hospital admissions related to fertility for the year ending March 2024

The data for contraceptive prescribing and hospital admissions related to fertility have also been revised for the previous year to account for updates to population estimates.

The tables provide data on contraceptive activity taking place at dedicated Sexual and Reproductive Health (SRH) services in England, as recorded in the Sexual and Reproductive Health Activity Dataset (SRHAD), a mandated collection for all providers of NHS SRH services. A limited amount of data is presented from other sources; sterilisations and vasectomies in NHS hospitals and contraceptives dispensed in the community.

All new STI diagnoses among people accessing sexual health services* in England. Data represent STI diagnoses among people who are resident in England. Data is presented by area of patient residence and include those residents in England and those with an unknown residence (data for those residents outside of England is not included). Data is expressed as a rate per 100,000 population.*Sexual health services providing STI related care (Levels 1, 2 or 3). Further details on the levels of sexual healthcare provision are provided in the Standards for the Management of STIs.

Rationale A summary figure of all new STI diagnoses.

Definition of numerator The number of new STI diagnoses among people accessing sexual health services in England who are also residents in England.STI data excluding chlamydia is sourced from the GUMCAD STI Surveillance System (Levels 2 and 3). GUMCAD data is reported by SHSs providing STI related care (Levels 2 or 3). Chlamydia data is sourced from GUMCAD (Level 3) and CTAD Chlamydia Surveillance System (Levels 1 and 2), UKHSA. CTAD data is reported by laboratories conducting testing for any service (Levels 1, 2 or 3) providing chlamydia testing.The Episode Activity codes (SNOMED or Sexual Health and HIV Activity Property Types (SHHAPT)) relating to diagnosis of: chancroid, Lymphogranuloma venereum (LGV), donovanosis, chlamydia, gonorrhoea, first episode anogenital herpes, new HIV diagnosis, molluscum contagiosum, non-specific genital infection (NSGI), pelvic inflammatory disease (PID) and epididymitis: non-specific, scabies and pediculosis pubis, syphilis (primary, secondary and early latent), trichomoniasis, first episode genital warts were used.In 2015, the new STI diagnoses group was expanded to include new codes that were not previously reported via GUMCADv2. The new codes include: Mycoplasma genitalium (C16); Shigella: flexneri, sonnei and unspecified (SG1, SG2, SG3).The clinical criteria used to diagnose the conditions are given at https://www.bashh.org/guidelines .Data was de-duplicated to ensure that a patient received a diagnostic code only once for each episode. Patients cannot be tracked between services and therefore de-duplication relies on patient consultations at a single service.

Definition of denominator The denominators for 2012 to 2022 are sourced from Office for National Statistics (ONS) population estimates based on the 2021 Census.Population estimates for 2023 were not available at the time of publication – therefore rates for 2023 are calculated using estimates from 2022 as a proxy.Further details on the ONS census are available from the https://www.ons.gov.uk/census .Caveats Every effort is made to ensure accuracy and completeness of GUMCAD data, including web-based reporting with integrated checks on data quality. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may differ from previous publications.Figures reported in 2020 and 2021 are notably lower than previous years due to the disruption to SHSs during the national response to the COVID-19 pandemic.

In 2023, there were approximately ***** cases of STIs diagnosed per 100,000 population in England among those from a black or black British ethnic background. This was the ethnic group with the highest rate of STIs diagnosed during this year. This statistic displays the rate of cases of sexually transmitted infections diagnosed in England in 2023, by ethnicity (per 100,000 population).

Contains statistics regarding contraceptive use among women aged under 50; women ‘at risk’ of pregnancy; sterilisations and vasectomies; sexual behaviour and condom use; and knowledge of sexually transmitted infections. Source agency: Office for National Statistics Designation: National Statistics Language: English Alternative title: Contraception and Sexual Health

Overview

The dataset titled "STI Diagnosis Numbers of England 2013-2022" provides a comprehensive overview of sexually transmitted infections (STIs) diagnosed over a decade. It covers a range of diseases, detailing annual diagnosis numbers and rates across different genders. The data is structured with diseases listed in rows and years in columns, offering an extensive timeline for analysis and trend observation.

What can be done and how to pre-process/transform the data.To leverage this dataset for insightful analysis, preprocessing steps should include:

1.Reformatting the Data: Transform the dataset so that years are rows instead of columns, making it easier to perform time-series analysis.

2.Cleaning and Structuring: Ensure that each disease and gender has its distinct row and column, respectively, and that all missing or unclear data is addressed.

3.Normalization: Consider normalizing the data, especially the rates per 100,000 population, for consistent comparisons across years and diseases.

Once preprocessed, the data can be used for trend analysis, predictive modeling, public health planning, and educational purposes. It can help identify prevalent STIs, understand demographic impacts, and shape future health initiatives.

We extend our deepest gratitude to the UK Health Security Agency and all associated parties for compiling and providing access to this crucial data. Their commitment to transparency and public health allows for continuous research, education, and improvement in sexual health services.

Final words

This dataset is not just numbers; it represents real people and the impact of STIs on communities over a decade. By analyzing these trends, we can contribute to better health outcomes, informed policy-making, and increased public awareness. Let's use this data responsibly and effectively to make a positive difference in public health.

In 2023, over *** thousand females and *** thousand males aged 25 to 34 years old attended specialist SHS in England. This statistic displays the number of individuals attending specialist sexual health services in England in 2023, by gender and age.

All chlamydia diagnoses among people accessing sexual health services* in England who are also residents in England, expressed as a rate per 100,000 population. Data is presented by area of patient residence and include those residents in England and those with an unknown residence (data for those residents outside of England is not included).*Sexual health services providing STI related care (Levels 1, 2 or 3). Further details on the levels of sexual healthcare provision are provided in the https://www.bashh.org/about-bashh/publications/standards-for-the-management-of-stis/ .RationaleChlamydia causes avoidable sexual and reproductive ill-health. While chlamydial infections are more commonly found among young adults aged under 25 years, women and men aged 25 years and over are also at-risk of chlamydia.Definition of numeratorThe number of chlamydia diagnoses among people accessing sexual health services in England. Includes those diagnosed through NHS and local authority commissioned testing and excludes those diagnosed through private testing.Chlamydia data is sourced from GUMCAD STI Surveillance System (Level 3) and CTAD Chlamydia Surveillance System (Levels 1 and 2), UKHSA. GUMCAD data is reported by SHSs providing STI related care (Levels 2 or 3). CTAD is reported by laboratories conducting testing for any service (Levels 1, 2 or 3) providing chlamydia testing.A maximum of one chlamydia test or diagnosis per individual is counted within a 6 week period. Any further tests or diagnoses within the 6 week period are not counted. Diagnoses are kept in preference over negative results during this process. Patients cannot be tracked between clinics and therefore de-duplication relies on patient consultations at a single service.The clinical definition used to diagnose chlamydia is given at https://www.bashh.org/guidelines .Definition of denominatorThe denominators for 2012 to 2022 are sourced from Office for National Statistics (ONS) population estimates based on the 2021 Census.Population estimates for 2023 were not available at the time of publication – therefore rates for 2023 are calculated using estimates from 2022 as a proxy.Further details on the ONS census are available from the https://www.ons.gov.uk/census .CaveatsEvery effort is made to ensure accuracy and completeness of GUMCAD data, including web-based reporting with integrated checks on data quality. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may differ from previous publications.Figures reported in 2020 and 2021 are notably lower than previous years due to the disruption to SHSs during the national response to the COVID-19 pandemic.

This publication primarily covers contraceptive activity taking place at dedicated Sexual and Reproductive Health (SRH) services in England, as recorded in the Sexual and Reproductive Health Activity Dataset (SRHAD), a mandated collection for all providers of NHS SRH services. Data from GP settings and pharmacies is not included (unless otherwise stated). People attend SRH services for a variety of reasons, but the main focus of this report is contraception.

All gonorrhoea diagnoses among people accessing sexual health services* in England who are also residents in England, expressed as a rate per 100,000 population. Data is presented by area of patient residence and include those residents in England and those with an unknown residence (data for those residents outside of England is not included).*Sexual health services providing STI related care (Levels 2 and 3). Further details on the levels of sexual healthcare provision are provided in the https://www.bashh.org/about-bashh/publications/standards-for-the-management-of-stis/ .RationaleGonorrhoea causes avoidable sexual and reproductive ill-health. Gonorrhoea is used as a marker for rates of unsafe sexual activity. This is because the majority of cases are diagnosed in sexual health clinics, and consequently the number of cases may be a measure of access to sexually transmitted infection (STI) treatment. Infections with gonorrhoea are also more likely than chlamydia to result in symptoms.Definition of numeratorThe number of gonorrhoea diagnoses among people accessing sexual health services in England who are also residents in England.Episode Activity codes (SNOMED or Sexual Health and HIV Activity Property Types (SHHAPT)) relating to diagnosis of gonorrhoea were used. The clinical criteria used to diagnose the conditions are given at https://www.bashh.org/guidelines .Data was de-duplicated to ensure that a patient received a diagnostic code only once for each episode. Patients cannot be tracked between services and therefore de-duplication relies on patient consultations at a single service.Definition of denominatorThe denominators for 2012 to 2022 are sourced from Office for National Statistics (ONS) population estimates based on the 2021 Census.Population estimates for 2023 were not available at the time of publication – therefore rates for 2023 are calculated using estimates from 2022 as a proxy.Further details on the ONS census are available from the https://www.ons.gov.uk/census .CaveatsEvery effort is made to ensure accuracy and completeness of GUMCAD data, including web-based reporting with integrated checks on data quality. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may differ from previous publications.Figures reported in 2020 and 2021 are notably lower than previous years due to the disruption to SHSs during the national response to the COVID-19 pandemic.

A set of key clinical indicators (KCIs) has been developed, for which data were first published in February 2006. The KCI reports are updated annually. Source agency: ISD Scotland (part of NHS National Services Scotland) Designation: National Statistics Language: English Alternative title: Key Clinical Indicators for Sexual Health

Sexual health services in York. For further information please visit City of York Council's website. *Please note that the data published within this dataset is a live API link to CYC's GIS server. Any changes made to the master copy of the data will be immediately reflected in the resources of this dataset.The date shown in the "Last Updated" field of each GIS resource reflects when the data was first published.

This publication covers activity taking place in the community at dedicated Sexual and Reproductive Health (SRH) services, including activity at non NHS service providers where available. SRH services include family planning services, community contraception clinics, integrated GUM and SRH services and young people's services e.g. Brook advisory centres. They provide a range of services including, but not exclusively, contraception provision and advice, sexual health treatment and advice, pregnancy related care, abortion related care, cervical screening, psychosexual therapy, PMS treatment, colposcopy services, fertility treatment and care and gynaecological treatment and care. A contact within this report may be a clinic attendance, or a contact with the service at a non-clinic venue such as home visits / outreach, or a non-face to face contact such as by telephone or e-mail. The data includes non-English residents using services based in England. This report excludes services provided in out-patient clinics, at community pharmacies and those provided by General Practitioners, unless otherwise stated.

Snapshot img

Sexually Transmitted Diseases (STD) Treatment Market Size 2025-2029

The sexually transmitted diseases treatment market size is valued to increase USD 24.21 billion, at a CAGR of 7% from 2024 to 2029. Increasing prevalence of STDs will drive the sexually transmitted diseases (std) treatment market.

Major Market Trends & Insights

North America dominated the market and accounted for a 47% growth during the forecast period.
By Type - Viral infections segment was valued at USD 36.7 billion in 2023
By Route Of Administration - Oral segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: USD 70.93 million
Market Future Opportunities: USD 24205.20 million
CAGR : 7%
North America: Largest market in 2023

Market Summary

The market encompasses a continually evolving landscape driven by the increasing prevalence of these conditions and advances in rapid diagnosis. Core technologies, such as nucleic acid amplification tests and point-of-care diagnostics, play a pivotal role in enhancing the accuracy and speed of STD detection. Applications of these technologies span various service types, including telemedicine, hospitals, and clinics. Despite advancements, challenges persist, including limited healthcare services in developing regions and the emergence of drug-resistant strains. Looking forward, opportunities abound, particularly in the development of novel therapeutics and vaccines.
As of 2021, the global market for STD diagnostics is estimated to account for approximately 20% of the overall infectious disease diagnostics market share. Related markets such as HIV and Hepatitis C virus (HCV) diagnostics also contribute significantly to the overall landscape. The ongoing evolution of the STD Treatment Market underscores the importance of staying informed and prepared for the future.

What will be the Size of the Sexually Transmitted Diseases (STD) Treatment Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Sexually Transmitted Diseases (STD) Treatment Market Segmented and what are the key trends of market segmentation?

The sexually transmitted diseases (STD) treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Viral infections
  Bacterial infections
  Others


Route Of Administration

  Oral
  Topical
  Injectable


End-user

  Hospital and clinics
  Diagnostic centers
  Individuals


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    Spain
    UK


  APAC

    China
    India
    Japan


  Rest of World (ROW)

By Type Insights

The viral infections segment is estimated to witness significant growth during the forecast period.

The market experiences significant growth due to the rising prevalence of viral infections, such as genital herpes caused by the herpes simplex virus, human papillomavirus (HPV) leading to genital warts and cervical cancer, hepatitis B, and AIDS caused by HIV. According to the Centers for Disease Control and Prevention (CDC), around 42-45% of adults aged 18-59 years in the US were infected with HPV during 2023 and 2024. Innovations in STD treatment include the development of combination therapies, rapid diagnostic tests, and antiviral therapies. Safe sex practices, such as condom usage, and public health initiatives focusing on STD testing methods, contact tracing, and disease surveillance contribute to market expansion.

However, challenges like drug interactions, antibiotic resistance, and healthcare disparities persist. Immune response plays a crucial role in treatment efficacy. Antiviral therapies and drug delivery systems aim to improve treatment adherence and patient outcomes. Molecular diagnostics and prevention strategies, such as HPV vaccination, sexual health education, and behavioral interventions, are essential in mitigating the long-term complications of STDs. The market for bacterial infections, such as gonorrhea and syphilis, also experiences growth due to the increasing incidence of these diseases. Pharmacokinetic modeling and treatment efficacy studies are ongoing to address the microbial pathogenesis and improve patient care.

The STD treatment market is expected to grow by approximately 12% in the next two years, with a similar expansion rate anticipated in the following period. The increasing prevalence of STDs, advancements in diagnostic tools, and the development of new treatment methods are key factors driving this growth. Additionally, the market is projected to reach a value of around 25 billion USD by 2026. In conclusion, the sexually transmitted diseases treatment market is a dynamic and evolving indu

All diagnoses of first episode genital herpes among people accessing sexual health services* in England who are also residents in England, expressed as a rate per 100,000 population. Data is presented by area of patient residence and include those residents in England and those with an unknown residence (data for those residents outside of England is not included).*Sexual health services providing STI related care (Levels 2 and 3). Further details on the levels of sexual healthcare provision are provided in the https://www.bashh.org/about-bashh/publications/standards-for-the-management-of-stis/ .RationaleGenital herpes is the most common ulcerative sexually transmitted infection seen in England. Infections are frequently due to herpes simplex virus (HSV) type 2, although HSV-1 infection is also seen. Recurrent infections are common with patients returning for treatment.Definition of numeratorThe number of diagnoses of genital herpes (first episode) among people accessing sexual health services in England who are also residents in England.Episode Activity codes (SNOMED or Sexual Health and HIV Activity Property Types (SHHAPT)) relating to diagnosis of genital herpes (first episode) were used. The clinical criteria used to diagnose the conditions are given at https://www.bashh.org/guidelines .Data was de-duplicated to ensure that a patient received a diagnostic code only once for each episode. Patients cannot be tracked between services and therefore de-duplication relies on patient consultations at a single service.Definition of denominatorThe denominators for 2012 to 2022 are sourced from Office for National Statistics (ONS) population estimates based on the 2021 Census.Population estimates for 2023 were not available at the time of publication – therefore rates for 2023 are calculated using estimates from 2022 as a proxy.Further details on the ONS census are available from the https://www.ons.gov.uk/census .CaveatsEvery effort is made to ensure accuracy and completeness of GUMCAD data, including web-based reporting with integrated checks on data quality. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may differ from previous publications.Figures reported in 2020 and 2021 are notably lower than previous years due to the disruption to SHSs during the national response to the COVID-19 pandemic.

Snapshot img

Sexually Transmitted Disease (STD) Testing Market Size 2024-2028

The sexually transmitted disease (std) testing market size is valued to increase USD 32.37 billion, at a CAGR of 5.6% from 2023 to 2028. Increasing prevalence of STDs will drive the sexually transmitted disease (std) testing market.

Major Market Trends & Insights

North America dominated the market and accounted for a 48% growth during the forecast period.
By Product - Laboratory testing device segment was valued at USD 53.60 billion in 2022
By Disease Type - Chlamydia segment accounted for the largest market revenue share in 2022

Market Size & Forecast

Market Opportunities: USD 64.43 billion
Market Future Opportunities: USD 32.37 billion
CAGR : 5.6%
North America: Largest market in 2022

Market Summary

The market encompasses the global industry dedicated to diagnosing and identifying various sexually transmitted infections. This market is marked by continuous evolution, driven by the increasing prevalence of STDs and advances in rapid diagnosis technologies. According to the World Health Organization, approximately one million sexually transmitted infections occur every day.
This underscores the growing demand for reliable and accessible testing solutions. However, challenges persist, particularly in developing regions where limited healthcare services hinder widespread testing and treatment. Despite these hurdles, opportunities abound for innovations in core technologies, such as point-of-care diagnostics and molecular testing, as well as in applications, including telemedicine and self-testing. These trends are shaping the future of the STD Testing Market, offering significant potential for growth and impact.

What will be the Size of the Sexually Transmitted Disease (STD) Testing Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Sexually Transmitted Disease (STD) Testing Market Segmented and what are the key trends of market segmentation?

The sexually transmitted disease (std) testing industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  Laboratory testing device
  POC testing device


Disease Type

  Chlamydia
  Gonorrhea
  Syphilis
  Trichomoniasis
  Others


End-User

  Hospitals & Clinics
  Diagnostic Laboratories
  Home Care Settings
  Research & Academic Institutes


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  Middle East and Africa

    Egypt
    KSA
    Oman
    UAE


  APAC

    China
    India
    Japan


  South America

    Argentina
    Brazil


  Rest of World (ROW)

By Product Insights

The laboratory testing device segment is estimated to witness significant growth during the forecast period.

The global STD testing market is experiencing significant growth due to the rising prevalence of sexually transmitted diseases (STDs), driven primarily by unprotected sex. Approximately 376 million new cases of STDs occur annually, with genital herpes, chlamydia, and gonorrhea being the most common. In response to this public health concern, various diagnostic techniques are being employed, including blood sample testing, genital swab collection, urine sample analysis, and antibody detection assays. The industry's expansion is further fueled by the increasing emphasis on preventative healthcare, stringent sexual health education, and the availability of rapid diagnostic tests. For instance, quantitative diagnostic results, such as viral load monitoring and genotyping, offer more precise and actionable information for clinical decision support.

Qualitative diagnostic results, like immunochromatographic assays, provide quick and easy-to-interpret results, making them ideal for point-of-care diagnostics. The introduction of molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid sequence-based amplification (NASBA), has significantly improved test sensitivity metrics and accuracy. These advancements enable early detection and effective treatment, reducing the false positive rate and false negative rate. Infection control measures, including disease prevalence estimates and test result reporting, are essential components of public health surveillance. Healthcare resource allocation and treatment guidelines are continually evolving to address the challenges posed by STDs, ensuring patient confidentiality and maintaining data privacy regulations.

Prevention strategies, such as condom use and vaccinations, play a crucial role in reducing the spread of STDs. Clinical decision support systems and test specificity metrics help healthcare professionals make informed decis

All infectious syphilis (primary, secondary and early latent) diagnoses among people accessing sexual health services* in England who are also residents in England, expressed as a rate per 100,000 population. Data is presented by area of patient residence and includes those residents in England and those with an unknown residence (data for those residents outside of England is not included).*Sexual health services providing STI related care (Levels 2 and 3). Further details on the levels of sexual healthcare provision are provided in the https://www.bashh.org/about-bashh/publications/standards-for-the-management-of-stis/ .RationaleSyphilis is an important public health issue in men who have sex with men (MSM) among whom incidence has increased over the past decade.Definition of numeratorThe number of infectious syphilis (primary, secondary and early latent) diagnoses among people accessing sexual health services in England who are also residents in England.Episode Activity codes (SNOMED or Sexual Health and HIV Activity Property Types (SHHAPT)) relating to diagnosis of infectious syphilis (primary, secondary and early latent) were used. The clinical criteria used to diagnose the conditions are given at https://www.bashh.org/guidelines .Data was de-duplicated to ensure that a patient received a diagnostic code only once for each episode. Patients cannot be tracked between clinics and therefore de-duplication relies on patient consultations at a single service.Definition of denominatorThe denominators for 2012 to 2022 are sourced from Office for National Statistics (ONS) population estimates based on the 2021 Census.Population estimates for 2023 were not available at the time of publication – therefore rates for 2023 are calculated using estimates from 2022 as a proxy.Further details on the ONS census are available from the https://www.ons.gov.uk/census .CaveatsEvery effort is made to ensure accuracy and completeness of GUMCAD data, including web-based reporting with integrated checks on data quality. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may differ from previous publications.Figures reported in 2020 and 2021 are notably lower than previous years due to the disruption to SHSs during the national response to the COVID-19 pandemic.